- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00162175
PPAR-COMBO With Sulfonylurea
September 10, 2010 updated by: Bristol-Myers Squibb
A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 in Combination With Glyburide Therapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Sulfonylurea Therapy Alone
A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 in Combination with Glyburide Therapy in Subjects with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sulfonylurea Therapy Alone.
Study Overview
Study Type
Interventional
Enrollment
534
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Buenos Aires, Argentina
- Local Institution
-
Cordoba, Argentina
- Local Institution
-
Mendoza, Argentina
- Local Institution
-
-
Buenas Aires
-
Bahia Blanca, Buenas Aires, Argentina
- Local Institution
-
-
Buenos Aires
-
Capital Federal, Buenos Aires, Argentina
- Local Institution
-
-
-
-
New South Wales
-
Canberra, New South Wales, Australia
- Local Institution
-
Wollongong, New South Wales, Australia
- Local Institution
-
-
Queensland
-
Brisbane, Queensland, Australia
- Local Institution
-
-
-
-
Para
-
Belem, Para, Brazil
- Local Institution
-
-
Parana
-
Curitiba, Parana, Brazil
- Local Institution
-
-
Rio Grande Do Sul
-
Porto Alegre, Rio Grande Do Sul, Brazil
- Local Institution
-
-
Sao Paulo
-
Marilia, Sao Paulo, Brazil
- Local Institution
-
-
-
-
-
St. John's, Canada
- Local Institution
-
-
Ontario
-
Corunna, Ontario, Canada
- Local Institution
-
Hawksbury, Ontario, Canada
- Local Institution
-
Sarnia, Ontario, Canada
- Local Institution
-
-
Quebec
-
Gatineau, Quebec, Canada
- Local Institution
-
Laval, Quebec, Canada
- Local Institution
-
St. Jerome, Quebec, Canada
- Local Institution
-
-
-
-
-
Broglie, France
- Local Institution
-
Chartres, France
- Local Institution
-
Gemenos, France
- Local Institution
-
-
D'Egletons
-
Rosiers, D'Egletons, France
- Local Institution
-
-
Sur Leze
-
Labarthe, Sur Leze, France
- Local Institution
-
-
Wesserling
-
Husseren, Wesserling, France
- Local Institution
-
-
-
-
-
Dresden, Germany
- Local Institution
-
Hamburg, Germany
- Local Institution
-
Nuernberg, Germany
- Local Institution
-
-
Schwenningen
-
Viernheim, Schwenningen, Germany
- Local Institution
-
-
-
-
-
Ravenna, Italy
- Local Institution
-
-
-
-
-
Durango, Mexico
- Local Institution
-
-
Baja California
-
Tijuana, Baja California, Mexico
- Local Institution
-
-
Distrito Federal
-
Mexico, Distrito Federal, Mexico
- Local Institution
-
-
Guanajuato
-
Leon, Guanajuato, Mexico
- Local Institution
-
-
New Mexico
-
Albuquerque, New Mexico, Mexico
- Local Institution
-
-
Nuevo Leon
-
Monterrey, Nuevo Leon, Mexico
- Local Institution
-
-
Yucatan
-
Merida, Yucatan, Mexico
- Local Institution
-
-
-
-
-
Deurne, Netherlands
- Local Institution
-
Ewyk, Netherlands
- Local Institution
-
Hoogvliet, Netherlands
- Local Institution
-
Rijswijk, Netherlands
- Local Institution
-
S Gravenhage, Netherlands
- Local Institution
-
Zwijndrecht, Netherlands
- Local Institution
-
-
-
-
-
Arequipa, Peru
- Local Institution
-
Lima, Peru
- Local Institution
-
-
-
-
-
Carolina, Puerto Rico
- Local Institution
-
Guaynabo, Puerto Rico
- Local Institution
-
Ponce, Puerto Rico
- Local Institution
-
Rio Piedras, Puerto Rico
- Local Institution
-
-
-
-
-
Moscow, Russian Federation
- Local Institution
-
Saratov, Russian Federation
- Local Institution
-
Smolensk, Russian Federation
- Local Institution
-
St. Petersburg, Russian Federation
- Local Institution
-
-
-
-
-
A Coruna, Spain
- Local Institution
-
Alicante, Spain
- Local Institution
-
Cadiz, Spain
- Local Institution
-
Granada, Spain
- Local Institution
-
La Coruna, Spain
- Local Institution
-
Madrid, Spain
- Local Institution
-
Oviedo, Spain
- Local Institution
-
Tenerife, Spain
- Local Institution
-
Teruel, Spain
- Local Institution
-
Zaragoza, Spain
- Local Institution
-
-
DE
-
Las Palmas, DE, Spain
- Local Institution
-
-
de Compostela
-
Santiago, de Compostela, Spain
- Local Institution
-
-
-
-
-
Swan Lane, United Kingdom
- Local Institution
-
-
Cambridgeshire
-
Soham, Cambridgeshire, United Kingdom
- Local Institution
-
-
East Sussex
-
Bexhill-on-Sea, East Sussex, United Kingdom
- Local Institution
-
-
Greater London
-
Sunbury on Thames, Greater London, United Kingdom
- Local Institution
-
-
Hampshire
-
Aldershot, Hampshire, United Kingdom
- Local Institution
-
-
Lanarkshire
-
Glasgow, Lanarkshire, United Kingdom
- Local Institution
-
-
Lancashire
-
Blackpool, Lancashire, United Kingdom
- Local Institution
-
-
Middlesex
-
Harrow, Middlesex, United Kingdom
- Local Institution
-
-
Sussex
-
Hastings, Sussex, United Kingdom
- Local Institution
-
-
Wiltshire
-
Bath, Wiltshire, United Kingdom
- Local Institution
-
-
Worcestershire
-
Inkberrow, Worcestershire, United Kingdom
- Local Institution
-
-
-
-
Alabama
-
Anniston, Alabama, United States
- Local Institution
-
Hoover, Alabama, United States
- Local Institution
-
Huntsville, Alabama, United States
- Local Institution
-
Mobile, Alabama, United States
- Local Institution
-
-
Arizona
-
Mesa, Arizona, United States
- Local Institution
-
Phoenix, Arizona, United States
- Local Institution
-
Tucson, Arizona, United States
- Local Institution
-
-
Arkansas
-
Little Rock, Arkansas, United States
- Local Institution
-
-
California
-
Encinitas, California, United States
- Local Institution
-
Long Beach, California, United States
- Local Institution
-
Los Angeles, California, United States
- Local Institution
-
Mission Viejo, California, United States
- Local Institution
-
Pasadena, California, United States
- Local Institution
-
San Diego, California, United States
- Local Institution
-
Walnut Creek, California, United States
- Local Institution
-
Westlake Village, California, United States
- Local Institution
-
-
Colorado
-
Colorado Springs, Colorado, United States
- Local Institution
-
Denver, Colorado, United States
- Local Institution
-
Loveland, Colorado, United States
- Local Institution
-
Wheat Ridge, Colorado, United States
- Local Institution
-
-
Florida
-
Chipley, Florida, United States
- Local Institution
-
Miami, Florida, United States
- Local Institution
-
New Port Richey, Florida, United States
- Local Institution
-
Pinellas Park, Florida, United States
- Local Institution
-
Vero Beach, Florida, United States
- Local Institution
-
Winter Park, Florida, United States
- Local Institution
-
-
Georgia
-
Dunwoody, Georgia, United States
- Local Institution
-
-
Illinois
-
Chicago, Illinois, United States
- Local Institution
-
-
Kansas
-
Overland Park, Kansas, United States
- Local Institution
-
-
Kentucky
-
Lexington, Kentucky, United States
- Local Institution
-
-
Louisiana
-
Slidell, Louisiana, United States
- Local Institution
-
-
Maryland
-
Chester, Maryland, United States
- Local Institution
-
Silver Springs, Maryland, United States
- Local Institution
-
-
Massachusetts
-
Springfield, Massachusetts, United States
- Local Institution
-
-
Michigan
-
Berkley, Michigan, United States
- Local Institution
-
Detroit, Michigan, United States
- Local Institution
-
-
Minnesota
-
Arden Hills, Minnesota, United States
- Local Institution
-
-
Mississippi
-
Gulfport, Mississippi, United States
- Local Institution
-
-
Missouri
-
Excelsior Springs, Missouri, United States
- Local Institution
-
Kansas City, Missouri, United States
- Local Institution
-
St. Louis, Missouri, United States
- Local Institution
-
-
New York
-
East Syracuse, New York, United States
- Local Institution
-
-
North Carolina
-
Charlotte, North Carolina, United States
- Local Institution
-
Greensboro, North Carolina, United States
- Local Institution
-
Hickory, North Carolina, United States
- Local Institution
-
Huntersville, North Carolina, United States
- Local Institution
-
Morehead City, North Carolina, United States
- Local Institution
-
Wilmington, North Carolina, United States
- Local Institution
-
-
Ohio
-
Cincinnati, Ohio, United States
- Local Institution
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States
- Local Institution
-
Tulsa, Oklahoma, United States
- Local Institution
-
-
Oregon
-
Corvallis, Oregon, United States
- Local Institution
-
Eugene, Oregon, United States
- Local Institution
-
Portland, Oregon, United States
- Local Institution
-
-
Pennsylvania
-
Altoona, Pennsylvania, United States
- Local Institution
-
Philadelphia, Pennsylvania, United States
- Local Institution
-
-
Rhode Island
-
Cranston, Rhode Island, United States
- Local Institution
-
-
South Carolina
-
Anderson, South Carolina, United States
- Local Institution
-
Duncan, South Carolina, United States
- Local Institution
-
Simpsonville, South Carolina, United States
- Local Institution
-
Summerville, South Carolina, United States
- Local Institution
-
-
Tennessee
-
Bristol, Tennessee, United States
- Local Institution
-
Kingsport, Tennessee, United States
- Local Institution
-
Knoxville, Tennessee, United States
- Local Institution
-
Memphis, Tennessee, United States
- Local Institution
-
-
Texas
-
Dallas, Texas, United States
- Local Institution
-
Houston, Texas, United States
- Local Institution
-
Irving, Texas, United States
- Local Institution
-
Lake Jackson, Texas, United States
- Local Institution
-
San Antonio, Texas, United States
- Local Institution
-
The Colony, Texas, United States
- Local Institution
-
-
Washington
-
Olympia, Washington, United States
- Local Institution
-
-
West Virginia
-
Bluefield, West Virginia, United States
- Local Institution
-
-
Wisconsin
-
Marshfield, Wisconsin, United States
- Local Institution
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Type 2 Diabetes, HbA1c > 7.0% and < 10.0%, mean serum triglyceride < 600 mg/dL, body mass index < 41 kg/m2, fasting c-peptide . 1.5 ng/mL.
Exclusion Criteria:
- History of MI (myocardial infarction), coronary angioplasty or bypass graft(s), valvular disease or repair, unstable angina pectoris, transient ischemic attack (TIA), cerebrovascular attack, or cerebrovascular accident (CVA) within 6 months, congestive heart failure (NYHA Class III and IV, uncontrolled hypertension, history or renal disease, peripheral vascular disease (PVD), pulmonary disease, gastrointestinal disease, active liver disease or endocrine disease.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Compare change from baseline in HbA1c after 24 weeks of treatment with muraglitazar + glyburide vs placebo + glyburide
|
Secondary Outcome Measures
Outcome Measure |
---|
Change in FPG from basline to W24, proportion of subjects receiving therapeutic response at W24, percent change of fasting lipid levels from baseline to W11/12, change in hs-CRP from baseline to W24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2003
Primary Completion (Actual)
November 1, 2005
Study Completion (Actual)
November 1, 2005
Study Registration Dates
First Submitted
September 9, 2005
First Submitted That Met QC Criteria
September 9, 2005
First Posted (Estimate)
September 13, 2005
Study Record Updates
Last Update Posted (Estimate)
September 14, 2010
Last Update Submitted That Met QC Criteria
September 10, 2010
Last Verified
September 1, 2007
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CV168-021
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metabolics Diabetes Nos
-
Bristol-Myers SquibbCompletedMetabolicsUnited States
-
University of AarhusCompletedComplications of Transplanted Organs and Tissue | Diabetes Mellitus Nos New OnsetDenmark
-
AstraZenecaBristol-Myers SquibbTerminated
-
Cairo UniversityCompleted
-
Eastern Cooperative Oncology GroupRecruitingMelanoma | Breast Cancer, NOS | CNS Primary Tumor, NOS | Cervical Cancer, NOS | Colorectal Cancer, NOS | Leukemia, NOS | Lymphoma, NOS | Miscellaneous Neoplasm, NOS | Non-Rhabdomyosarcoma Soft Tissue Sarcoma, NOS | Testicular Nonseminomatous Germ Cell Tumor, NOS | Thyroid Cancer, NOS | Bone Cancer, NOSUnited States
-
Bristol-Myers SquibbCompletedCANCER,NOSFrance, Canada, United States, Switzerland, Spain, Italy
-
University of Texas Southwestern Medical CenterCompleted
-
Bristol-Myers SquibbCompleted
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)Terminated
-
University of BelgradeCompletedDiabetes Mellitus, Type 2 | Surgery | Tooth Extraction Status NosSerbia
Clinical Trials on Muraglitazar
-
Bristol-Myers SquibbCompletedDiabetes, Type 2United States, Canada, Mexico, Puerto Rico, Australia, Poland, Taiwan
-
Bristol-Myers SquibbCompletedDiabetes Mellitus IIUnited States, Italy, Spain, Argentina, Brazil, Mexico, Netherlands, Puerto Rico, Canada, Sweden, Australia, Poland, France, United Kingdom, Czech Republic, South Africa
-
Bristol-Myers SquibbMerck Sharp & Dohme LLCCompletedDiabetes Mellitus, Type 2United States, Italy
-
Bristol-Myers SquibbCompletedDiabetes MellitusUnited States, Argentina, Brazil, Canada, Mexico, Peru, Puerto Rico, Australia, Korea, Republic of, Sweden, United Kingdom, France
-
Bristol-Myers SquibbCompletedType 2 DiabetesUnited States, Canada, Puerto Rico, Mexico
-
Bristol-Myers SquibbCompletedDyslipidemiaUnited States, Canada
-
Merck Sharp & Dohme LLCBristol-Myers SquibbTerminatedType 2 Diabetes Mellitus
-
Bristol-Myers SquibbMerck Sharp & Dohme LLCCompletedDiabetes Mellitus, Type 2United States, Chile, Hong Kong, Argentina, Austria, Brazil, Canada, Mexico, Peru, Puerto Rico, Philippines, Thailand, Russian Federation, Poland, Germany, Taiwan, Switzerland
-
Bristol-Myers SquibbMerck Sharp & Dohme LLCCompletedType 2 Diabetes MellitusUnited States, Argentina, Canada, Mexico, Peru, Taiwan, Australia, Philippines, Thailand, Brazil, Chile, India, Russian Federation, Ukraine